An interventional study of WISH Adherence and WISH Parenting in HIV/AIDS, sponsored by University of Pennsylvania. Completed at 7 sites in United States. Open to female participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by University of Pennsylvania · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Acquired Immunodeficiency Syndrome by University of Pennsylvania — 1 open to participants now, 4 under way, none of them phase 3. Acquired Immunodeficiency Syndrome · University of Pennsylvania.
Among the 31 studies in Acquired Immunodeficiency Syndrome by University of Pennsylvania, this one is the 20th largest by enrollment of the 30 interventional ones that give a count, is one of 4 that started in 2020, is one of 20 with no phase, and was the 23rd registered.
3,039 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.
Browse Acquired Immunodeficiency Syndrome studies →1 of the 31 studies in Acquired Immunodeficiency Syndrome by University of Pennsylvania is open now, in 1 country. Recruiting first, the newest first:
University of Pennsylvania · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 197 Acquired Immunodeficiency Syndrome studies recruiting now, 117 (59%) set no upper age limit and 67 (34%) stop at 75 or younger; 43 take children under 18; 68 take healthy volunteers.
This study: 16 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 4 · Phase 3 3 · Phase 4 1
First in 2004; this study’s year is marked. 4 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 151 is above the median of 96 across 2,254 interventional studies indexed under Acquired Immunodeficiency Syndrome.
Median enrollment 243 across the 30 interventional studies, 80 across the 1 observational. Of the 26 that completed or were terminated, 12 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Pennsylvania is the lead sponsor of 1,668 studies on the registry; 229 are open to participants now.
Of its 160 completed or terminated interventional studies of FDA-regulated products, 110 (69%) have results posted.
1 of the studies in Acquired Immunodeficiency Syndrome by University of Pennsylvania that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03617198University of PennsylvaniaCD4 CAR+ ZFN-modified T Cells in HIV Therapy | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 31 studies in Acquired Immunodeficiency Syndrome by University of Pennsylvania, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to test the efficacy of a theory-driven peer intervention for pregnant and postpartum women living HIV. The peer intervention is designed to increase self-efficacy, social support, self-regulatory behaviors, and outcome expectancy in order to improve retention in care and viral suppression postpartum. The intervention will consist of face-to-face prenatal educational sessions, starting in early third trimester, and postpartum sessions scheduled up to three months postpartum.
Despite significant progress in the reduction of perinatal transmission of HIV, there has been less attention to retaining women living with HIV (WLH) in care in the postpartum period. Retention in care particularly affects black and Hispanic women as they are disproportionately affected by the HIV epidemic in the United States (U.S.). In preliminary work, the investigators used HIV surveillance data from the Philadelphia Department of Public Health to examine the HIV care continuum of 561 women, 78% of whom were black, during pregnancy and up to two years postpartum (2005-2011). Only 38% of women received HIV care within 3 months after delivery, and retention remained poor at 1 (39%) and 2 (25%) years postpartum. Poor maternal retention in care also occurs in Mississippi, Georgia, and New York, demonstrating that this break in the HIV care continuum is widespread. Retaining WLH in care positively impacts their well-being and health postpartum and for years to come, which promotes not only their health but that of their newborns. Therefore, the long-term goal of this study is to decrease HIV disparities by increasing WLH's retention in care in the postpartum period.
Presently, there are a limited number of evidence-based interventions aimed at improving retention in care for WLH. Through a critical review of research literature, the investigators found that interventions to improve retention in care have been implemented in low-resource countries, but studies in high-resource countries are lacking. In sub-Saharan Africa, the use of peers has resulted in significantly higher maternal retention and viral suppression compared to standard of care. Peers are WLH who remained engaged in HIV care postpartum, and provide education and support to WLH in the prenatal and postpartum periods. The investigators also conducted a series of qualitative interviews with WLH in the U.S. to evaluate factors contributing to poor retention in care postpartum, and to assess the acceptability and feasibility of a peer intervention in meeting women's needs. The results showed that women's primary motivation to engage in prenatal care is to keep their infant healthy, but that many of them experience significant life challenges that impede their ability to engage in care postpartum. However, they expressed great interest in receiving support from a peer to motivate sustained engagement in care postpartum.
The investigators propose to test the efficacy of a theory-driven peer intervention, based on the integrated model of health behavior. The peer intervention, Women Involved in Supporting Health (WISH), is designed to increase self-efficacy, social support, self-regulatory behaviors, and outcome expectancy in order to improve retention in care and viral suppression postpartum. The intervention will consist of three face-to-face prenatal sessions, starting in early third trimester, and two face-to-face postpartum sessions scheduled up to three months postpartum. The prenatal sessions focus on knowledge that will address barriers to outcome expectancies and self-efficacy, and the postpartum sessions build on outcome expectancy and knowledge to develop skills tailored to adherence to antiretroviral therapy and engagement in HIV care. Between the sessions, the peer and the WLH will communicate via text messages, phone calls and/or video chat. The randomized controlled trial (RCT) will take place across Center for AIDS Research sites in Philadelphia, the District of Columbia, Atlanta, and Birmingham, where HIV infection rates remain disproportionally high among black and Hispanic women. A total of 260 pregnant WLH will be randomized to either WISH adherence or an attention-matched WISH parenting control group.
The impact of this research will be the development of the first evidence-based peer intervention to address the pressing need to improve postpartum retention in HIV care and viral suppression of WLH in the U.S.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Women randomized to the adherence arm will attend 3 prenatal sessions and 2 postpartum sessions with a peer facilitator. Each session will be delivered on an individual basis and consist of structured educational content followed by unstructured conversation, allowing the participant to ask questions and actively engage in formulating her plan to be retained in HIV care. The goal of the prenatal sessions is to introduce the intervention, foster bonding, and address outcome expectancies and self-efficacy regarding retention in HIV care postpartum. The postpartum sessions build on outcome expectancies and self-efficacy to develop skills for Antiretroviral therapy (ART) adherence and engagement in HIV care.
Behavioral: WISH Adherence
Women randomized to the parenting control arm will also attend 3 prenatal sessions and 2 postpartum sessions with a peer facilitator. The educational sessions will be focused on parenting and baby care.
Behavioral: WISH Parenting
The educational sessions will consist of an adherence-centered curriculum.
The educational sessions will focus on parenting and baby care.
Retention in Care up to 1 Year Postpartum
≥1 visit with an HIV provider in each 6-month interval of the postpartum year with ≥60 days between visits.
Time frame: Baseline through 1 year after delivery
Viral Suppression up to 1 Year Postpartum
Viral Load ≤ 200 copies/mL using the last available Viral Load up to 180 days before the end of the postpartum year.
Time frame: Baseline through 1 year after delivery
From March 2020 to August 2024, 151 participants were randomized. Pregnant women aged ≥16 years receiving prenatal and/or HIV care at participating clinics were recruited during the second or third trimester.
| Milestone | Adherence | Parenting |
|---|---|---|
| Started | 77 | 74 |
| Completed | 72 | 61 |
| Not completed | 5 | 13 |
| Withdrew: Lost to follow-up | 3 | 13 |
| Withdrew: Withdrew consent | 2 | 0 |
≥1 visit with an HIV provider in each 6-month interval of the postpartum year with ≥60 days between visits.
| Participants | Adherence | Parenting |
|---|---|---|
| Retained | 44 | 42 |
| Not Retained | 33 | 32 |
Viral Load ≤ 200 copies/mL using the last available Viral Load up to 180 days before the end of the postpartum year.
| Participants | Adherence | Parenting |
|---|---|---|
| Suppressed | 58 | 49 |
| Not Suppressed/Undocumented | 19 | 25 |
Collected over From enrollment up to 1 year after delivery. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Adherence | 0/77 (0%) | 0/77 (0%) | 0/77 (0%) |
| Parenting | 0/74 (0%) | 0/74 (0%) | 0/74 (0%) |
| Age, Continuous(Years) | Adherence | Parenting | Total |
|---|---|---|---|
| Mean | 30 ± 6 | 31 ± 6 | 31 ± 6 |
| Sex: Female, Male(Participants) | Adherence | Parenting | Total |
|---|---|---|---|
| Female | 77 | 74 | 151 |
| Male | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Adherence | Parenting | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 66 | 61 | 127 |
| White | 6 | 6 | 12 |
| More than one race | 2 | 5 | 7 |
| Unknown or Not Reported | 3 | 1 | 4 |
| Ethnicity (NIH/OMB)(Participants) | Adherence | Parenting | Total |
|---|---|---|---|
| Hispanic or Latino | 6 | 14 | 20 |
| Not Hispanic or Latino | 71 | 60 | 131 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Baseline Retention (One Year Pre-Pregnancy)(Participants) | Adherence | Parenting | Total |
|---|---|---|---|
| Retained | 28 | 29 | 57 |
| Not Retained | 38 | 32 | 70 |
| New Diagnosis | 11 | 13 | 24 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2020 to primary completion in Sep 2025, 66 months.
Results were first posted in Nov 2026, 1 year 1 month after primary completion. A results delay was requested in Aug 2026.
Of 642 non-industry interventional studies with no phase under Acquired Immunodeficiency Syndrome, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 45. This study's 66 months is above that.
Counting every sponsor, half of 648 studies reached it within 29 months; a quarter within 17 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Acquired Immunodeficiency Syndrome →